Lining Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lining Zheng has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Cecilia Leal
Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
5 shared publications - Amogh Vaidya
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications - Ankit Gupta
Center for Alzheimer’s and Neurodegenerative Diseases, Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications - Daniel John Siegwart
Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications - Erick Guerrero
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications Jeffrey G. McDonald
Center for Human Nutrition, Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (8) , 1320
Publisher Correction: High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
- 4 June 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (8) , 1320
Open AccessPublisher Correction: High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
- 4 April 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (8) , 1807-1816
Click Lipid Nanoparticles for the Delivery of mRNA to Metabolically Labeled Cancer Cells
Lipid nanoparticle (LNP)-based mRNA delivery has a lot of potential in combating a wide range of diseases, but delivering mRNA to specific cell types continues to be challenging. Despite recent advances in organ and cell specificity, the majority of clinical LNP systems cannot fully release their payload to a targeted site. Incorporating active targeting moieties into LNPs is highly desired to expand nanomedicine applications. In this Letter, we developed LNPs that harness the power of bioorthogonal "click" azide-alkyne chemical reactions. We show that the plasma membranes of cancer cells can be labeled with azide groups by metabolic sugar labeling, and these azide groups can react with dibenzocyclooctyne (DBCO) on LNPs to achieve specific binding. To achieve this, we synthesized new and versatile lipids by functionalizing DBCO groups to phospholipids with or without a poly(ethylene glycol) (PEG) linker. The DBCO lipids were successfully formulated into DBCO-LNPs comprising other standard lipid compounds. When using these DBCO-LNPs to deliver mRNA to metabolically labeled cells, DBCO-LNPs showed a remarkable ability to preferentially deliver mRNA to azide-labeled cells. Removing PEG linkers from DBCO lipids enables better integration and retention in the LNP, and the higher the amount of DBCO lipid, the stronger the targeting effect. This work demonstrates that cell-specific targeting can be achieved utilizing azide-alkyne ″click″ chemistry and could inspire the development of the next generation of LNPs for active cyto-tropic nanomedicines.
- 4 April 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (8) , 1807-1816
Click Lipid Nanoparticles for the Delivery of mRNA to Metabolically Labeled Cancer Cells
Lipid nanoparticle (LNP)-based mRNA delivery has a lot of potential in combating a wide range of diseases, but delivering mRNA to specific cell types continues to be challenging. Despite recent advances in organ and cell specificity, the majority of clinical LNP systems cannot fully release their payload to a targeted site. Incorporating active targeting moieties into LNPs is highly desired to expand nanomedicine applications. In this Letter, we developed LNPs that harness the power of bioorthogonal "click" azide-alkyne chemical reactions. We show that the plasma membranes of cancer cells can be labeled with azide groups by metabolic sugar labeling, and these azide groups can react with dibenzocyclooctyne (DBCO) on LNPs to achieve specific binding. To achieve this, we synthesized new and versatile lipids by functionalizing DBCO groups to phospholipids with or without a poly(ethylene glycol) (PEG) linker. The DBCO lipids were successfully formulated into DBCO-LNPs comprising other standard lipid compounds. When using these DBCO-LNPs to deliver mRNA to metabolically labeled cells, DBCO-LNPs showed a remarkable ability to preferentially deliver mRNA to azide-labeled cells. Removing PEG linkers from DBCO lipids enables better integration and retention in the LNP, and the higher the amount of DBCO lipid, the stronger the targeting effect. This work demonstrates that cell-specific targeting can be achieved utilizing azide-alkyne ″click″ chemistry and could inspire the development of the next generation of LNPs for active cyto-tropic nanomedicines.
- Top Cited Papers
- 28 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (11) , 1840-1851
High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
Messenger RNA lipid-nanoparticle-based therapies represent an emerging class of medicines for a variety of applications. However, anti-poly(ethylene glycol) (anti-PEG) antibodies generated by widely used PEGylated medicines and lipid nanoparticles hinder therapeutic efficacy upon repeated dosing. Here we report the chemical design, synthesis and optimization of high-density brush-shaped polymer lipids that reduce anti-PEG antibody binding to improve protein production consistency in repeated dosing. Brush-shaped polymer lipid parameters, including side chain length, degree of polymerization, anchor alkyl length and surface regimes on lipid nanoparticles modulate anti-PEG antibody binding affinity and control their blood circulation pharmacokinetics. Compared to widely used 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, lipid nanoparticles containing brush-shaped polymer lipids generate superior therapeutic outcomes in protein replacement therapy and genome editing models, reformulating structure–activity guidelines for the design of PEG lipid substitutes. Overall, these findings contribute to the general effort in the development of lipid nanoparticles with low immunogenicity to overcome current roadblocks to nucleic acid medicines.
- 28 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (11) , 1840-1851
Top Cited PapersHigh-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
Messenger RNA lipid-nanoparticle-based therapies represent an emerging class of medicines for a variety of applications. However, anti-poly(ethylene glycol) (anti-PEG) antibodies generated by widely used PEGylated medicines and lipid nanoparticles hinder therapeutic efficacy upon repeated dosing. Here we report the chemical design, synthesis and optimization of high-density brush-shaped polymer lipids that reduce anti-PEG antibody binding to improve protein production consistency in repeated dosing. Brush-shaped polymer lipid parameters, including side chain length, degree of polymerization, anchor alkyl length and surface regimes on lipid nanoparticles modulate anti-PEG antibody binding affinity and control their blood circulation pharmacokinetics. Compared to widely used 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, lipid nanoparticles containing brush-shaped polymer lipids generate superior therapeutic outcomes in protein replacement therapy and genome editing models, reformulating structure–activity guidelines for the design of PEG lipid substitutes. Overall, these findings contribute to the general effort in the development of lipid nanoparticles with low immunogenicity to overcome current roadblocks to nucleic acid medicines.
- Top Cited PapersOpen Access
- 26 June 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (27)
Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
RNA therapeutics have the potential to resolve a myriad of genetic diseases. Lipid nanoparticles (LNPs) are among the most successful RNA delivery systems. Expanding their use for the treatment of more genetic diseases hinges on our ability to continuously evolve the design of LNPs with high potency, cellular-specific targeting, and low side effects. Overcoming the difficulty of releasing cargo from endocytosed LNPs remains a significant hurdle. Here, we investigate the fundamental properties of nonviral RNA nanoparticles pertaining to the activation of topological transformations of endosomal membranes and RNA translocation into the cytosol. We show that, beyond composition, LNP fusogenicity can be prescribed by designing LNP nanostructures that lower the energetic cost of fusion and fusion–pore formation with a target membrane. The inclusion of structurally active lipids leads to enhanced LNP endosomal fusion, fast evasion of endosomal entrapment, and efficacious RNA delivery. For example, conserving the lipid make-up, RNA–LNPs having cuboplex nanostructures are significantly more efficacious at endosomal escape than traditional lipoplex constructs.
- 26 June 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (27)
Top Cited PapersOpen AccessLipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
RNA therapeutics have the potential to resolve a myriad of genetic diseases. Lipid nanoparticles (LNPs) are among the most successful RNA delivery systems. Expanding their use for the treatment of more genetic diseases hinges on our ability to continuously evolve the design of LNPs with high potency, cellular-specific targeting, and low side effects. Overcoming the difficulty of releasing cargo from endocytosed LNPs remains a significant hurdle. Here, we investigate the fundamental properties of nonviral RNA nanoparticles pertaining to the activation of topological transformations of endosomal membranes and RNA translocation into the cytosol. We show that, beyond composition, LNP fusogenicity can be prescribed by designing LNP nanostructures that lower the energetic cost of fusion and fusion–pore formation with a target membrane. The inclusion of structurally active lipids leads to enhanced LNP endosomal fusion, fast evasion of endosomal entrapment, and efficacious RNA delivery. For example, conserving the lipid make-up, RNA–LNPs having cuboplex nanostructures are significantly more efficacious at endosomal escape than traditional lipoplex constructs.
- Open Access
Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
RNA therapeutics have the potential to resolve a myriad of diseases caused by gene deficiency. Lipid nanoparticles (LNPs) are one of the most successful RNA delivery systems. However, expanding their application hinges on the discovery of next generation LNPs with high potency, cyto-specific targeting, and low side effects. Overcoming the difficulty of releasing cargo from endocytosed LNPs remains a significant hurdle. The endosomal escape of viral and non-viral nanoparticles relies on the topological transformation of membrane fusion pore formation followed by RNA translocation into the cytosol. In this study we show that LNP-RNA nanostructure modulates the energetic cost of LNP fusion with a target membrane. The inclusion of a new class of structurally-active lipids leads to superior LNP endosomal fusion, fast evasion of endosomal entrapment, and efficacious RNA delivery. Specifically, bicontinuous cubic RNA-LNPs, cuboplexes , have significantly higher endosomal escape rates and deliver more RNA compared to regular lamellar LNPs.
Open AccessLipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
RNA therapeutics have the potential to resolve a myriad of diseases caused by gene deficiency. Lipid nanoparticles (LNPs) are one of the most successful RNA delivery systems. However, expanding their application hinges on the discovery of next generation LNPs with high potency, cyto-specific targeting, and low side effects. Overcoming the difficulty of releasing cargo from endocytosed LNPs remains a significant hurdle. The endosomal escape of viral and non-viral nanoparticles relies on the topological transformation of membrane fusion pore formation followed by RNA translocation into the cytosol. In this study we show that LNP-RNA nanostructure modulates the energetic cost of LNP fusion with a target membrane. The inclusion of a new class of structurally-active lipids leads to superior LNP endosomal fusion, fast evasion of endosomal entrapment, and efficacious RNA delivery. Specifically, bicontinuous cubic RNA-LNPs, cuboplexes , have significantly higher endosomal escape rates and deliver more RNA compared to regular lamellar LNPs.